Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Biogen announces phase 2 data for cutaneous lupus erythematosus treatment
Biogen presented 52-week Phase 2 data for litifilimab, showing rapid and durable improvements in skin disease activity for cutaneous lupus erythematosus.
Marvel Biosciences' MB-204 Shows Activity Across Multiple Autism Behaviors
Preclinical data shows Marvel Biosciences' MB-204 matched or outperformed Istradefylline in improving behaviors associated with Phelan-McDermid syndrome.
Viatris builds in pain relief with the $1.65bn Pacira BioSciences purchase
Viatris has offered $1.65 billion to acquire Pacira BioSciences, aiming to add non-opioid pain therapies Exparel and Zilretta to its portfolio.
The Nobel Prize in Chemistry 2026: How Chemistry Chooses a Mirror Image
Henri B. Kagan and Kenso Soai win the 2026 Nobel Prize in Chemistry for discoveries in asymmetric synthesis, autocatalysis and homochirality.
Litfulo Phase III data support Pfizer’s push into systemic vitiligo treatment
Pfizer's Phase III trials demonstrate Litfulo's efficacy in nonsegmental vitiligo, supporting its plan to submit data to global regulatory authorities.
Experimental cancer drug works differently than researchers originally thought
A study reveals that the experimental cancer drug zavondemstat blocks the DHODH enzyme rather than KDM4, altering our understanding of its mechanism.
Bayer pledges $2.2bn to US manufacturing facility
Bayer has committed $2.2 billion to build a new, modular pharmaceutical manufacturing campus in Ohio, expected to serve global and domestic markets.
Click claims FDA okay for first-in-class schizophrenia DTx
Click Therapeutics received FDA clearance for Motivista, a digital therapeutic shown to significantly reduce negative symptoms in schizophrenia patients.
FDA Approval Opens New Treatment Path for ESR1-Mutated Breast Cancer
The FDA granted full approval to imlunestrant and abemaciclib for ESR1-mutated advanced breast cancer, shifting the treatment paradigm.
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets favors Merck’s pipeline strategy to offset the Keytruda patent cliff over Bristol Myers Squibb's efforts to replace Opdivo and Eliquis.
Two-Drug Combo Supercharges Liver Cancer Therapy in Preclinical Study
A preclinical study demonstrates that combining regorafenib with experimental checkpoint inhibitor BMS-1 produces synergistic effects in liver cancer.
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Sanofi and Regeneron are expanding their immunology collaboration in a deal worth up to $8 billion to co-develop four new long-acting antibodies.
3
4
5
6
7
8
9
10
11